In a large Swedish rheumatoid arthritis cohort, the incidence of thyroid disease declines after RA diagnosis vs the general population, with the effect strongest among those treated with anti-rheumatic drugs.
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs, but the effect was not found at 24 weeks.
Up to half of RA patients in the United States use long-term glucocorticoids despite previous work suggesting they increase MACE in a dose-dependent way.
Efficacy, safety findings for the use of TNF inhibitors vs other biologic disease-modifying antirheumatic drugs in treating RA-ILD contrast with those of some smaller observational studies.